Structures affecting recovery of macular function in patients with age-related macular degeneration after intravitreal ranibizumab

Nishimura, Tomoharu; Machida, Shigeki; Hashizume, Kouhei; Kurosaka, Daijiro

doi:10.1007/s00417-014-2779-z

Cited by 5 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the group free of SRD at 6 months showed better vision improvement than that with SRD, despite receiving fewer retreatments. Nishimura et al, [ 18 ] studying eyes with AMD treated with IVR, reported that SRD thickness correlated negatively with the a-wave amplitude on electroretinography. In other words, SRD has an important association with macular functions.…”

Section: Discussionmentioning

confidence: 99%

Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity

Mori

Takada²,

Yuzawa³

2018

Medicine

View full text Add to dashboard Cite

This study aimed to explore predictors of long-term stabilization of polypoidal choroidal vasculopathy (PCV) lesions and vision in response to injection of intravitreal ranibizumab (IVR). The treated eyes had a baseline best corrected visual acuity (BCVA) of at least 0.6 (logarithm of the minimal angle of resolution (logMAR) 0.22).We treated 45 eyes showing BCVA between 0.6 (logMAR 0.22) and 1.0 (logMAR 0), with IVR for 3 consecutive months. All eyes were confirmed to have subfoveal PCV prior to starting this treatment regimen. Additional IVR was administered at the subsequent monthly visits, if necessitated by evidence of persistent PCV, for up to 23 months after the first ranibizumab injection. The subjects were then carefully followed-up for 24 months, allowing detailed retrospective evaluation of changes in mean BCVA, central retinal thickness (CRT), serous retinal detachment (SRD), hemorrhage, and polypoidal lesion numbers. The relationships between retreatment and each of the baseline characteristics and SRD development during follow-up were analyzed.The mean logMAR BCVAs were 0.111 ± 0.076, 0.068 ± 0.206 (P = .0033) and 0.115 ± 0.265 (P = .27) at baseline and at 12 and 24 months, respectively. At 24 months, 87% of eyes had BCVA of 20/40 or better. Not requiring retreatment between 12 and 23 months was found to be significantly associated with the absence of retinal pigment epithelial detachment (RPED) at baseline (odds ratio: 0.262 (95% confidence interval (CI): 0.073–0.946). The rates of retreatment from 12 to 23 months were significantly higher in eyes with SRD at 6 and 12 months than in those without SRD (P = .004 and P < .001).In conclusion, during 24 months of antivascular endothelial growth factor (VEGF) therapy using ranibizumab for PCV, BCVA was maintained in those with good visual acuity at baseline. Comprehensive analyses revealed RPED at baseline and SRD development during follow-up to correlate significantly with the need for retreatment between 12 and 23 months. Our observations might facilitate tailoring treatments to individual PCV patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity

Mori

Takada²,

Yuzawa³

2018

Medicine

View full text Add to dashboard Cite

show abstract

Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results

Nishimura

Machida

2018

Jpn J Ophthalmol

View full text Add to dashboard Cite

Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion

et al. 2019

View full text Add to dashboard Cite

Structures affecting recovery of macular function in patients with age-related macular degeneration after intravitreal ranibizumab

Abstract: The macular function measured by the fmERGs was determined by the parafoveal outer layer and SRD thickness in patients with exudative AMD. Of these, changes in the SRD thickness by IVRs most strongly affected the recovery of macular function.

Cited by 5 publications

References 26 publications

Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity

Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity

Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results

Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion

Contact Info

Product

Resources

About